TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01498406

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: The investigators will carry out a two-armed prospective pilot study of the influence of vitD on cutaneous lupus (CLE) disease severity. Patients with CLE will be eligible for an observational or interventional arm based on their 25(OH)D levels and consent. Subjects with low vitD status (\<30 ng/mL) will be eligible for the investigational arm involving participation in a randomized controlled trial of daily high dose (4000 IU) vs. low dose (400 IU) vitD supplementation for 8 months. Subjects who have sufficient vitD status (\>30ng/mL) or those with low vitD who choose not to participate in the RCT are eligible for continued participation in the observational arm of the study. All subjects will be followed at 4, 8, and 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: The investigators will carry out a two-armed prospective pilot study of the influence of vitD on cutaneous lupus (CLE) disease severity. Patients with CLE will be eligible for an observational or interventional arm based on their 25(OH)D levels and consent. Subjects with low vitD status (\<30 ng/mL) will be eligible for the investigational arm involving participation in a randomized controlled trial of daily high dose (4000 IU) vs. low dose (400 IU) vitD supplementation for 8 months. Subjects who have sufficient vitD status (\>30ng/mL) or those with low vitD who choose not to participate in the RCT are eligible for continued participation in the observational arm of the study. All subjects will be followed at 4, 8, and 12 months.
Study: NCT00304278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib (Tarceva)
Description: 150 mg daily X 7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial Cisplatin (PLAT)
Description: 1 dose (150 mg/sq) per week X 4 weeks
Study: NCT02543736

Intervention type: DEVICE
Group type: OTHER
Intervention: Instrumented Treadmill System
Description: Patients will perform twice a gait and a balance analysis on an instrumented treadmill system combined to a photoelectric cell system while controls will only perform once.
Study: NCT02505711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Homestead Food Production program
Description: Training and support for vegetable gardening and poultry rearing, and education on young child nutrition, hygiene and health topics, in women's groups, as designed by the international non-governmental organization (NGO) Helen Keller International (HKI).
Study: NCT02544945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printed bolus
Description: Using the Cat Scan for treatment planning, a 3D plastic shell can be produced which is shaped exactly to the shape of the patient's chest wall. This shell will act as bolus - the substance that is placed on the skin during chest wall radiotherapy. The bolus allows the right dose of radiotherapy to get to the skin and the underlying chest wall.
Study: NCT03725982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No Laevo ®
Description: The subjects will not wear any supporting device to perform the experiment, which serves as the control condition.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No Laevo ®
Description: The subjects will not wear any supporting device to perform the experiment, which serves as the control condition.
Study: NCT02544945

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard bolus
Description: A standard 5mm-thick piece of rubber is placed on the patient's chest wall
Study: NCT01259518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRIN2755
Description: In treatment schedule A (Group A), the planned starting dose to be investigated is 25 mg TriN 2755 given once followed by a recovery period of 4 weeks. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after infusion (end of Cycle 1) does not indicate relevant toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRIN2755
Description: In treatment schedule B (Group B), the starting dose to be investigated is 800mg, given once every 7 days in a 4 week cycle. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after the start of the first infusion (end of Cycle 1) does not indicate relevant toxicity.
Study: NCT04677582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vidas Activas, famiLias saludablEs (VALE)
Description: Families and Children allocated to the intervention will receive weekly group-based meetings over a 10-week period consisting of education and activities on healthy lifestyles. Graduate students/Research Assistants trained in nutrition, exercise and clinical psychology will lead the meetings. All activities will be culturally relevant (i.e. cooking healthy Latino recipes) and Spanish speaking students will be recruited to deliver the intervention. Participants will be involved on deciding activities and projects and while some sessions will meet as a family group with parents/guardians, others will meet separately.
Study: NCT02601911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: 10 mg Ketorolac tromethamine is applied 45 minutes before the injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 10 mg Ketorolac tromethamine/ 1000mg Acetaminophen application before injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group receive the caplet including placebo 45 minutes before the injection.
Study: NCT00524134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol-CR
Description: Week 1: 20mg capsule once daily Week 2-3: 40mg capsule once daily Week 4-15: 80mg once daily Week 16: tapering (40mg/day x 4d, then 20mg/day x 3d), unless the patient wishes to continue receiving the medication.
Study: NCT03808506

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal calprotectin
Description: Stool test to look at baseline burden of inflammation
Study: NCT04576208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidiarrheal prophylaxis
Description: Antidiarrheal prophylaxis includes loperamide tablet administered as per routine clinical practice.
Study: NCT04856995

Intervention type: OTHER
Intervention: exposure to surgical smoke during surgery
Description: No intervention was made. During the surgery, complaints and throat cultures were taken before and after exposure to surgical smoke. Simultaneously, 45 air samples are taken in the operating room before, during and after the operation.
Study: NCT03526952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Delivered Intervention for Sexual Re-Adjustment
Description: Couples will meet with a therapist via video-conferencing for two 1.5-hr sessions. The therapist will facilitate couples' communication about their sexual and intimate relationship while providing psychoeducation about couple coping and sexuality after cancer and with an ostomy. Discussion will focus on current concerns, motivations for sex, relational strengths, and intimacy and sensual pleasure. Couples will also be encouraged to practice a sensate focusing exercise between sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written Educational Material
Description: Couples will receive written educational material for patients coping with changes in intimacy and sexuality when living with a permanent ostomy. This educational material is published by the United Ostomy Associations of America, Inc. and is available for free download from their website. Couples will have two weeks to read this material.
Study: NCT02239887

Intervention type: DEVICE
Intervention: WaveCrest LAA occlusion device
Description: Left Atrial Appendage Occlusion
Study: NCT04365946

Intervention type: PROCEDURE
Intervention: Gastroscopy
Description: Upper GI endoscopy and biopsy
Study: NCT01767545

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone implant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone implant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Study: NCT02626182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: active sildenafil
Study: NCT02626182

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sugar pill that looks like sildenafil tablets
Study: NCT01410695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib 3 mg
Study: NCT03400540

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: verbal instruction
Description: Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
Study: NCT01410695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib 6.0 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Study: NCT00724282

Intervention type: DRUG
Group type: OTHER
Intervention: Eszopiclone
Description: Eszopiclone 3 mg by mouth daily at bedtime for 9 days
Study: NCT01410695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (methotrexate)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (methotrexate)
Study: NCT00724282

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo by mouth daily at bedtime for 9 days
Study: NCT01432366

Intervention type: OTHER
Intervention: SC anti-TNF
Description: Subcutaneous (SC) anti-TNF
Study: NCT03207412

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAECs
Description: human amniotic epithelial cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAECs
Description: human amniotic epithelial cells
Study: NCT01410695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (masitinib)
Study: NCT02926183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel
Description: Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on day 1, 8, and 15 evey 4 weeks as one cycle of regimen.
Study: NCT00956683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Infraclavicular Nerve Block
Description: Use of Ultrasound to help guide needle placement and local anesthetic injection during infraclavicular nerve block.
Study: NCT03207412

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive implantation
Description: Minimally invasive implantation with ultrasound guidance
Study: NCT03278665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4SC-202 in combination with Pembrolizumab
Description: 4SC-202 in combination with Pembrolizumab
Study: NCT00956683

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dual-Endpoint nerve stimulation
Description: Use of dual-endpoint nerve stimulation to guide needle placement and local anesthetic injection during infraclavicular nerve block.
Study: NCT04087382

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thrombectomy
Description: Transfemoral a microcatheter with its distal end was positioned a few millimeters beyond the distal aspect of the clot, the guide wire was exchanged by Solitaire stent device. The device was held in place when 3 mm was out of the microcatheter. The microcatheter was slowly pulled back to deploy the TR or ST device over the clot.

Intervention type: OTHER
Group type: OTHER
Intervention: non intervention group
Description: medical treatment (Asprin, statin, nootropic drug)
Study: NCT02437890

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061
Study: NCT00304278

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RAD)
Description: 5 days per week X 7 weeks
Study: NCT00518310

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZAPRED
Description: The initial dose of prednisone will be 0.5 mg/kg/day for 4 weeks, then 0.25 mg/kg/day for 8 weeks. The dose will continue to decrease at a rate of 5 to 10 mg per week, to a dose of 0.25 or 0.125 mg/kg/day. Azathioprine will be given at a dose of 2-3 mg/kg/day (max 100 mg).
Study: NCT04489446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Patients allocated to this arm will receive Sildenafil 25mg every 8 hours orally for up to seven consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients allocated to this arm will receive a matching placebo similar to Sildenafil pills used in the intervention arm. Placebos will be delivered orally every 8 hours for up to seven consecutive days.
Study: NCT02437890

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061
Study: NCT04431323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESPRIMO
Description: Participants will receive the intervention during Phase 2.~The intervention is based on the cognitive behavioral, the third-wave (mindfulness and acceptance and commitment therapy), and the positive psychology approach.~The frequency of the intervention and the specific content and aims of the psychological and physical intervention will be based on the results of the surveys and the focus group discussion (Pre-phase and Phase 1). In order to maximize the benefit of the integrated intervention, all the three components of the interventions (i.e., psychological, motor exercise and social components) will be administered in the same time period.~A preliminary theoretical framework of the intervention will be created prior to the survey phase according to the literature in the field. Specific aspects of this preliminary framework will be discussed during the co-creation phase and adapted after the analysis of the qualitative results.
Study: NCT02437890

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02148783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: This is an open-labeled 4 week methylphenidate administration, 30 mg twice daily by mouth. Placebo and methylphenidate will also be administered as a single dose before one of the two PET and TMS sessions, in a single blinded manner (the participant will not know whether active drug or placebo was administered). PET imaging with \[11C\]-raclopride, a D2/D3 receptor ligand will be performed after administration of placebo or oral methylphenidate to measure endogenous DA release in TBI patients. Structural MRI will be performed before methylphenidate administration. TMS after placebo or methylphenidate will be performed to measure intracortical inhibition and dopaminergic activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03165643

Intervention type: DIAGNOSTIC_TEST
Intervention: OGTT
Description: 75 g glucose tolerance test was provided to all pregnant women during 24-28 weeks.

Intervention type: DIAGNOSTIC_TEST
Intervention: OGTT
Description: 75 g glucose tolerance test was provided to all pregnant women during 24-28 weeks.
Study: NCT02614937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 0.5 mg IVT ranibizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 0.5 mg IVT ranibizumab
Study: NCT03518047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: rizankizumab subcutaneous (SC) infusion
Study: NCT02614937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 0.5 mg IVT ranibizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Squalamine Lactate Ophthalmic Solution, 0.2%
Description: Squalamine Lactate Ophthalmic Solution BID
Study: NCT03518047

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for rizankizumab
Description: placebo for rizankizumab subcutaneous (SC) infusion
Study: NCT02515500

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gradual Cessation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gradual Cessation w/ Quitbit
Study: NCT01347099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy
Description: Internet-delivered CBT. Contact with therapist thru an e-mail system. 10 weeks
Study: NCT02614937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Squalamine Lactate Ophthalmic Solution, 0.2%
Description: Squalamine Lactate Ophthalmic Solution BID
Study: NCT03666039

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trainings app
Description: Sensorimotor trainings app for at home Training (tablet-based)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trainings app
Description: Sensorimotor trainings app for at home Training (tablet-based)
Study: NCT04073043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Coaching
Description: Access to Telephone Coaching for a period of 12 weeks
Study: NCT02924103

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contamination free bacterial swab
Description: A comparison of the bacteriology in bacterial swabs (Eswab 481CE, Copan Diagnostics, Italy) from the middle meatus. On the RIGHT side using the Contamination free bacterial swab introduction device that facilitates the introduction of a bacterial swab into the nose without direct or indirect contact with the nasal vestibule.
Study: NCT01343511

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human cord blood mononuclear cells
Description: Participants will be given rehabilitation therapy plus hCB-MNCs transplantation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells
Description: Participants will be given rehabilitation therapy plus and hCB-MNCs and hUC-MSCs transplantation.
Study: NCT02932618

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: von Willebrand factor (Recombinant)
Description: Lyophilized powder and solvent to prepare solution for injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: von Willebrand factor (Recombinant)
Description: Lyophilized powder and solvent to prepare solution for injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: von Willebrand factor (Recombinant)
Description: Lyophilized powder and solvent to prepare solution for injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antihemophilic Factor (Recombinant)
Description: Packaged in single boxes with 2 glass vials, with one vial containing the lyophilized ADVATE and the second vial containing the diluent.
Study: NCT01418261

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation (Symplicity Catheter System)

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Renal angiogram

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Renal angiogram
Study: NCT01068873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir plus maraviroc
Description: Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.
Study: NCT01297192

Intervention type: DRUG
Group type: OTHER
Intervention: solifenacin succinate
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: solifenacin succinate
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: mirabegron
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: mirabegron
Description: Oral
Study: NCT01493531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad
Description: Tablets, 200 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad
Description: Tablets, 400 mg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Placebo QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Allopurinol
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Tablets
Study: NCT02932618

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antihemophilic Factor (Recombinant)
Description: Packaged in single boxes with 2 glass vials, with one vial containing the lyophilized ADVATE and the second vial containing the diluent.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antihemophilic Factor (Recombinant)
Description: Packaged in single boxes with 2 glass vials, with one vial containing the lyophilized ADVATE and the second vial containing the diluent.
Study: NCT04265755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI).
Study: NCT02624804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Educator Therapy
Description: Patients will receive apheresis and then have their own blood returned to them with the educated lymphocytes
Study: NCT01917526

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oxygen mask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oxygen cannula
Study: NCT00446316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antacids (Mg-Al-based)
Description: the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatimib Mesylate (Gleevec®)
Description: Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatimib Mesylate (Gleevec®)
Description: Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.